Cargando...
Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
BACKGROUND: For most patients, pancreatic adenocarcinoma responds poorly to treatment, and novel therapeutic approaches are needed. Standard-of-care paclitaxel (PTX), combined with birinapant (BRP), a bivalent mimetic of the apoptosis antagonist SMAC (second mitochondria-derived activator of caspase...
Guardado en:
| Publicado en: | BMC Cancer |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7583190/ https://ncbi.nlm.nih.gov/pubmed/33097020 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07398-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|